Tech Company Financing Transactions
Menlo Therapeutics Funding Round
Menlo Therapeutics, based in Redwood City, secured $50 million from venBio, Aisling Capital and Bay City Capital.
Transaction Overview
Company Name
Announced On
7/19/2017
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors
Proceeds Purpose
This funding round follows the successful completion of two phase 2 clinical trials: TCP-101 evaluated subjects with chronic pruritus from multiple underlying causes, and TCP-102 studied subjects with chronic pruritus associated with prurigo nodularis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Cardinal Way 2nd Floor
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
Menlo Therapeutics Inc. is a clinical stage pharmaceutical company dedicated to the development of serlopitant, a once-daily oral NK-1 receptor antagonist, for the treatment of chronic pruritus and chronic cough.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Domzalski
Chief Financial Officer
Andrew Saik
Chief Scientific Officer
Iain Stuart
Vice President
Russell Elliott
VP - Bus. Development
Matthew Wiley
VP - General Counsel
Mutya Harsch
VP - Human Resources
Ray Steitz
Browse more venture capital transactions:
Prev: 7/19/2017: Alation venture capital transaction
Next: 7/19/2017: ObEN venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs